VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/03/Vivet-VTX-801-FDA-Fast-Track-Designation-2-1024x602.png)
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
Gene Therapy aims to be a one-time treatment that may stop or slow the progression of Wilson disease
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/03/ASGCT-Wilson-disease-1.jpg)
Learn how gene therapy aims to target the cause of Wilson disease by delivering a working ATP7B gene into cells. ClinicalTrials are now open for this investigational therapy.
Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/03/HGT-2021-1.jpg)
Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s PFIC Gene Therapy Programs
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/03/PR_Vivet-Mirum-1-1024x594.png)
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Vivet and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for WD
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/03/Logo-GatewayCT_pour-site-web-Section-News1-1-1024x931.jpg)
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/03/Pfizer_KC-site-1.png)
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet’s lead program, VTX-801 for Wilson Disease, highlighted during Pfizer’s Investor Day September 15th 2020
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/03/VTX-801_Pfizer-Investor-Day-1-1024x540.png)
Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020.
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation.
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/DNA-490376259-1-1024x683.jpg)
PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration
Happy to share the March 2020 Info Wilson newsletter from ABPWilson!
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/APBW-March-Newsletter.png)
Vivet is very happy to share the March 2020
Vivet Announces Publication in Nature Communications of VTX-803 Preclinical Data
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/nature-communications-vector-logo.png)
Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803